Insight from gastroenterology specialists on implications for treating patients with ulcerative colitis with newer novel therapies as recently presented at DDW 2021.
Andres Yarur, MD, of the Medical College of Wisconsin, comments on the chronic, progressive nature of ulcerative colitis and highlights special considerations for classifying patients based on disease severity.
Maria T. Abreu, MD, of the University of Miami Health System, explains how goals of treatment for ulcerative colitis have changed in recent years and reacts to changes in managing the disease.
Implications for treating patients with ulcerative colitis with novel S1P receptor modulators based on data revealed by the phase 2 OASIS trial, which has now led to a phase 3 study, ELEVATE UC 52.
Drs Maria T. Abreu and Timothy Ritter comment on limitations faced by providers who treat patients with ulcerative colitis and highlight strategies under investigation that can improve how the disease is managed.